

Inventors: Lipton and Okamoto
Serial No.: 09/876,187
Filed: June 5, 2001
Page 2

have been mapped by deletion analysis. PKC, protein kinase C site; MAPK, mitogen-activated protein kinase site; CKII casein kinase II site. CaMKIV, calcium-calmodulin kinase IV site. MEF2A motifs 1 to 4 are shown as SEQ ID NOS: 13 to 16, respectively. MEF2C motifs 1 to 4 are shown as SEQ ID NOS: 17 to 20, respectively. MEF2D motifs 1 to 3 are shown as SEQ ID NOS: 21 to 23, respectively. The calcium calmodulin kinase IV site is shown as SEQ ID NO: 24.--

Attached as Appendix A is a marked up version of the claim amendment. Text to be added is underlined.

REMARKS

The Brief Description of the Drawings has been amended in regard to Figure 1B in order to correct an oversight whereby the calcium calmodulin kinase IV sequence shown in original Figure 1B was not assigned a sequence identification number. No new matter is added by this amendment.

Inventors: Lipton and Okamoto
Serial No.: 09/876,187
Filed: June 5, 2001
Page 3

CONCLUSION

Should the Examiner have any questions, she is invited to call the undersigned agent or Cathryn Campbell.

Respectfully submitted,

May 9, 2003
Date

Andrea L. Gashler
Andrea L. Gashler
Registration No. 41,029
Telephone No.: (858) 535-9001
Facsimile No.: (858) 535-8949

McDERMOTT, WILL & EMERY
4370 La Jolla Village Drive
Suite 700
San Diego, California 92122

Inventors: Lipton and Okamoto
Serial No.: 09/876,187
Filed: June 5, 2001

APPENDIX A

are phosphorylated by p38 and ERK5 are marked with asterisks. Not all potential phosphorylation sites are shown. Some of the conserved stretches overlap with transactivation domains that have been mapped by deletion analysis. PKC, protein kinase C site; MAPK, mitogen-activated protein kinase site; CKII casein kinase II site. CaMKIV, calcium-calmodulin kinase IV site. MEF2A motifs 1 to 4 are shown as SEQ ID NOS: 13 to 16, respectively. MEF2C motifs 1 to 4 are shown as SEQ ID NOS: 17 to 20, respectively. MEF2D motifs 1 to 3 are shown as SEQ ID NOS: 21 to 23, respectively. The calcium calmodulin kinase IV site is shown as SEQ ID NO: 24.



BEST COPY OF SEQUENCE LISTING;

PAGES 1 THROUGH 21.

Attorney Client-Matter No.: 066654-622 (P-LJ 4714)

Serial No.: 09/876,187

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Sequence, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on May 9, 2003.

By Andrea L. Gashler
Andrea L. Gashler, Reg. No. 41,029

May 9, 2003
Date of Signature